See more : Prakash Woollen & Synthetic Mills Limited (PWASML.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Esperion Therapeutics, Inc. (ESPR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Esperion Therapeutics, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- T&K Toka Co., Ltd. (4636.T) Income Statement Analysis – Financial Results
- Guangdong Anjubao Digital Technology Co., Ltd. (300155.SZ) Income Statement Analysis – Financial Results
- Hubei Jiuzhiyang Infrared System Co., Ltd (300516.SZ) Income Statement Analysis – Financial Results
- ZOO Digital Group plc (ZOO.L) Income Statement Analysis – Financial Results
- Phoenix Pioneer technology Co., Ltd. (6920.TWO) Income Statement Analysis – Financial Results
Esperion Therapeutics, Inc. (ESPR)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.esperion.com
About Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 116.33M | 75.48M | 78.45M | 227.55M | 148.36M | 184.47M | 0.00 | 0.00 | 0.00 | 0.00 | 4.98B | 0.00 | 0.00 | 0.00 | 0.00 | 2.00K | 0.00 |
| Cost of Revenue | 43.27M | 26.97M | 14.22M | 2.39M | 175.61M | 265.00K | 258.00K | 252.00K | 236.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 786.00K | 683.22K |
| Gross Profit | 73.07M | 48.51M | 64.23M | 225.16M | -27.25M | 184.21M | -258.00K | -252.00K | -236.00K | 0.00 | 4.98B | 0.00 | 0.00 | 0.00 | 0.00 | -784.00K | -683.22K |
| Gross Profit Ratio | 62.81% | 64.27% | 81.88% | 98.95% | -18.36% | 99.86% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | -39,200.00% | 0.00% |
| Research & Development | 86.11M | 118.93M | 105.98M | 146.94M | 175.61M | 171.49M | 147.60M | 57.87M | 29.80M | 25.30M | 16.01M | 8.00M | 7.81M | 21.99M | 21.45M | 21.79M | 8.48M |
| General & Administrative | 126.92M | 97.78M | 171.29M | 180.32M | 65.85M | 33.10M | 21.38M | 18.28M | 20.24M | 10.92M | 6.74M | 2.21M | 2.36M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 15.60M | 11.30M | 13.70M | 19.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 142.52M | 109.08M | 184.99M | 199.62M | 65.85M | 33.10M | 21.38M | 18.28M | 20.24M | 10.92M | 6.74M | 2.21M | 2.36M | 5.96M | 5.02M | 2.95M | 2.52M |
| Other Expenses | 0.00 | 2.65M | 3.98M | 515.00K | 4.06M | 2.78M | 2.19M | 1.55M | 776.00K | 119.00K | 194.01K | -83.65K | -75.81K | 0.00 | 0.00 | 5.00M | 3.20M |
| Operating Expenses | 228.63M | 228.01M | 290.96M | 346.55M | 241.47M | 204.59M | 168.98M | 76.15M | 50.04M | 36.22M | 22.76M | 10.20M | 10.16M | 29.24M | 29.33M | 26.79M | 11.69M |
| Cost & Expenses | 271.90M | 254.98M | 305.18M | 348.94M | 241.47M | 204.59M | 168.98M | 76.15M | 50.04M | 36.22M | 22.76M | 10.20M | 10.16M | 29.24M | 29.33M | 27.57M | 12.37M |
| Interest Income | 0.00 | 2.60M | 112.00K | 600.00K | 4.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 58.98M | 56.81M | 46.35M | 22.67M | 8.12M | 100.00K | 198.00K | 376.00K | 520.00K | 270.00K | 936.58K | 1.49M | 577.16K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 164.00K | 500.00K | 612.00K | 547.00K | 319.00K | 265.00K | 258.00K | 252.00K | 236.00K | 160.00K | 70.55K | 139.43K | 178.47K | -1.29M | -2.01M | -2.05M | -683.22K |
| EBITDA | -150.11M | -176.35M | -222.14M | -120.33M | -88.73M | -204.32M | -166.53M | -74.35M | -49.03M | -36.06M | -22.69M | -10.12M | -10.06M | -27.22M | -26.80M | -25.52M | -11.69M |
| EBITDA Ratio | -129.03% | -234.31% | -283.96% | -53.12% | -60.02% | -110.90% | 0.00% | 0.00% | 0.00% | 0.00% | -0.45% | 0.00% | 0.00% | 0.00% | 0.00% | -1,086,150.00% | 0.00% |
| Operating Income | -155.56M | -179.50M | -226.73M | -121.40M | -93.10M | -204.59M | -168.98M | -76.15M | -50.04M | -36.22M | -22.76M | -10.20M | -10.16M | -27.95M | -27.32M | -27.57M | -12.37M |
| Operating Income Ratio | -133.72% | -237.83% | -289.02% | -53.35% | -62.75% | -110.90% | 0.00% | 0.00% | 0.00% | 0.00% | -0.46% | 0.00% | 0.00% | 0.00% | 0.00% | -1,378,600.00% | 0.00% |
| Total Other Income/Expenses | -53.69M | -54.16M | -42.38M | -22.16M | -4.06M | 2.78M | 1.99M | 1.17M | 256.00K | -151.00K | -3.33M | -1.54M | -652.97K | -780.00K | 2.39M | -3.80M | 0.00 |
| Income Before Tax | -209.25M | -233.66M | -269.11M | -143.55M | -97.17M | -201.81M | -166.99M | -74.98M | -49.78M | -36.38M | -26.09M | -11.74M | -10.82M | -28.73M | -24.93M | -31.37M | 0.00 |
| Income Before Tax Ratio | -179.87% | -309.58% | -343.04% | -63.09% | -65.49% | -109.40% | 0.00% | 0.00% | 0.00% | 0.00% | -0.52% | 0.00% | 0.00% | 0.00% | 0.00% | -1,568,550.00% | 0.00% |
| Income Tax Expense | 0.00 | 54.16M | 49.72M | 22.64M | 11.86M | 2.88M | 2.13M | 1.67M | 1.06M | 229.00K | 1.13M | 1.40M | 501.34K | 2.07M | 468.00K | 4.10M | -331.84K |
| Net Income | -209.25M | -287.82M | -318.82M | -166.19M | -109.02M | -201.81M | -166.99M | -74.98M | -49.78M | -36.38M | -26.09M | -11.74M | -10.82M | -28.73M | -24.93M | -27.58M | -10.67M |
| Net Income Ratio | -179.87% | -381.34% | -406.42% | -73.04% | -73.48% | -109.40% | 0.00% | 0.00% | 0.00% | 0.00% | -0.52% | 0.00% | 0.00% | 0.00% | 0.00% | -1,378,800.00% | 0.00% |
| EPS | -2.03 | -4.33 | -11.03 | -6.05 | -4.02 | -7.54 | -6.98 | -3.33 | -2.26 | -2.22 | -1.71 | -1.22 | -1.13 | -6.86 | -6.38 | -9.35 | -7.94 |
| EPS Diluted | -2.03 | -4.33 | -11.03 | -6.05 | -4.02 | -7.54 | -6.98 | -3.33 | -2.26 | -2.22 | -1.70 | -1.22 | -1.13 | -6.86 | -6.38 | -9.35 | -7.94 |
| Weighted Avg Shares Out | 103.11M | 66.41M | 28.90M | 27.47M | 27.09M | 26.75M | 23.93M | 22.54M | 22.02M | 16.37M | 15.29M | 9.61M | 9.61M | 4.19M | 3.91M | 2.95M | 1.34M |
| Weighted Avg Shares Out (Dil) | 103.11M | 66.41M | 28.90M | 27.47M | 27.09M | 26.75M | 23.93M | 22.54M | 22.02M | 16.37M | 15.34M | 9.61M | 9.61M | 4.19M | 3.91M | 2.95M | 1.34M |
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on August 7, 2024, the Company granted 18 new employees 66,800 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan.
Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Esperion Therapeutics (ESPR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) –
Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility
– OMERS Life Sciences to Purchase Esperion's European Royalty on Bempedoic Acid Products for $304.7 Million with European Royalties Reverting to Esperion Once OMERS Receives 1.7 Times its Investment –
Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget
Fundamentally, biotech stocks to buy operate on a clear and unavoidable narrative: wealth means nothing without health. You hear various stories about extremely wealthy tycoons throwing all kinds of money, not just for lifesaving procedures but in more superficial efforts...
3 Penny Stocks to Buy if You Want to Spend Less and Earn More
Investing in penny stocks can be a thrilling way to explore the potential for substantial gains. Despite their inherent risks, these stocks often appeal to adventurous investors looking to diversify their portfolios without breaking the bank.
Why Is Esperion Therapeutics (ESPR) Up 14.2% Since Last Earnings Report?
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?
Esperion's (ESPR) Drugs Get EU Nod for Lowering Heart Risk
Esperion's (ESPR) Nilemdo & Nustendi get the European Commission's nod for label expansion based on data from the CLEAR Outcomes study.
Esperion to Participate in Upcoming June Investor Conferences
ANN ARBOR, Mich., May 23, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of May, which can be found on our investor relations website.
Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia
ANN ARBOR, Mich., May 20, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) and Otsuka Pharmaceutical Co., Ltd (Otsuka) announced today that the primary endpoint was achieved in the Phase 3 trial in Japan for bempedoic acid as a potential treatment...
Source: https://incomestatements.info
Category: Stock Reports